Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan maintains an Overweight rating on Health Catalyst (NASDAQ:HCAT) but lowers the price target from $15 to $14.

June 06, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Health Catalyst but lowers the price target from $15 to $14, indicating a slightly less optimistic outlook.
The Overweight rating suggests continued confidence in Health Catalyst's performance, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100